Clearside Biomedical, Inc. Enrolls First Patient in Phase 3 Clinical Trial of CLS-TA Using Suprachoroidal Drug Administration

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical-stage biopharmaceutical firm developing drugs for the eye, announces its 1st patient enrolled in Phase 3 trial for macular edema associated with non-infectious uveitis